Every dollar spent on COVID-19 vaccine development and distribution generated an estimated $59.70 to $809 in health and economic value during the first year that vaccines were given, according to new research published in the journal PLOS Medicine and reported by MedicalXpress and Tech Times. The study is the first global analysis of the return on investment for COVID-19 vaccines.
Researchers from New York University, the London School of Hygiene and Tropical Medicine and Imperial College London drew on data from 173 countries to compare the costs of vaccine development, manufacturing and delivery against the health and economic benefits, according to Tech Times. Overall, vaccine development and delivery worldwide cost $79.4 billion, while the resulting health and economic benefits were valued at between $6.43 trillion and $64.3 trillion, according to the study published on 5 November 2026.
Readers should note that the wide range reflects two different ways of valuing the benefits. The lower figure, $6.43 trillion, comes from a cost-effectiveness analysis, the standard health-economics approach using quality-adjusted life years, while the much higher figure, $64.3 trillion, comes from a cost-benefit analysis that asks how much people would pay to reduce their own risk of death, according to Tech Times. Death prevention alone accounted for roughly $63.5 trillion of the higher total. Some outlets round the return as $81 to $810 per dollar; this article uses the paper's own figures of $59.70 to $809.
The study evaluated the first year vaccines were available, from 8 December 2020 to 8 December 2021, when they had the greatest impact because people had limited immunity, according to MedicalXpress. In that year, the researchers estimate, vaccines prevented about 1.50 billion infections and 51.5 million hospitalisations, and averted between 14 million and 20 million deaths, depending on the mortality statistics used, according to Tech Times. High-income countries saw the greatest health benefits per person vaccinated, while low-income countries gained the greatest non-health benefits per person vaccinated when expressed as a share of GDP per capita, according to the paper's abstract.
The figures are modelled estimates, and the authors note limitations: the study relies on earlier analyses of vaccination impact and looks only at the first year of the programme, when rates of infection were lower afterwards and most people had developed some immunity, according to MedicalXpress. Even so, the authors conclude that rapid vaccine development and delivery were an excellent investment, and that vaccine development and fair distribution around the world should be a priority before and during future health crises.